Courtesy of Benzinga.
Illumina (NASDAQ: ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics (NASDAQ: GNOM). Illumina is seeking all available remedies, including injunctive relief.
The new suit, filed in the U.S. District Court for the Southern District of California, is based on Complete Genomics’ infringement of U.S. Patent No. 8,192,930, entitled “Method for Sequencing a Polynucleotide Template.” The suit targets Complete Genomics’ Combinatorial Probe-Anchor Ligation (cPal) read technology.
Illumina previously sued Complete Genomics for infringement of U.S. Patent No. 6,306,597, in the U.S. District Court for the Northern District of California. On February 8, 2012, the Court in that case issued a Claim Construction Order providing the Court’s interpretation of the disputed patent terms which affirmed the breadth of the patent and supports Illumina’s position that Complete Genomics infringes that patent.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.
